Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegylated interferon alfa-2a salvage monotherapy in high-risk polycythemia vera or essential thrombocythemia
2010-019500-23Phase 2Active
- Sponsor
- Consorzio Mario Negri Sud
- Start
- Jan 2012
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of peginterferon alfa-2a in polycythemia vera (PV) and thrombocythemia, sponsored by Consorzio Mario Negri Sud. Primary endpoint: Complete response. Started Jan 2012; status: active.
02
Drugs
peginterferon alfa-2a
03
Conditions
polycythemia vera (PV)thrombocythemia
Beyond the preview
Go deeper on 2010-019500-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-019500-23.